~ Calico Life Sciences LLC (Calico), a biotechnology organization founded by Alphabet and Arthur D. Levinson, Ph.D., has announced the appointment of Dr. Michael Lenardo as its new Chief Scientific Officer. This news comes as Calico continues to focus on the biology of aging and age-related diseases.

Dr. Lenardo, an accomplished molecular immunologist and geneticist with over four decades of experience in medical research, will join Calico in August after completing his term as Co-Director of the National Institute of Allergy and Infectious Diseases (NIAID) Clinical Genomics Program at the National Institutes of Health.

According to Dr. Levinson, CEO of Calico, securing someone of Dr. Lenardo's caliber for this role is a major achievement for the company. He praised Dr. Lenardo's outstanding scientific background, collaborative nature, and track record of innovation and leadership, stating that these qualities will serve Calico well as they continue to advance their mission.

In addition to his current role at NIAID, Dr. Lenardo also serves as an NIH Distinguished Investigator and Chief of Molecular Development of the Immune System section at the institute. He has been with NIAID since 1989 when he established an independent research unit there.

More on Missouriar
Throughout his career, Dr. Lenardo has been recognized for his work on fundamental immunological mechanisms and is particularly known for his discoveries related to the genetic basis, pathogenesis, and treatment of congenital disorders of the immune system. He has received numerous awards and designations such as membership into the National Academy of Sciences and the National Academy of Medicine.

Dr. Lenardo's impressive academic background includes a bachelor's degree in Natural Sciences from Johns Hopkins University and a medical degree from Washington University in St. Louis. He completed his residency in internal medicine and research in biochemistry at the University of Iowa before performing postdoctoral training with Nobel laureates David Baltimore and Phillip Sharp at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.

In his new role as Chief Scientific Officer, Dr. Lenardo will be responsible for leading Calico's scientific efforts as they continue to strive towards understanding the biology of aging and developing interventions to promote longer and healthier lives. He expressed his excitement about joining Calico, stating that their commitment to scientific excellence and integrity, along with their highly talented team, is truly impressive and reflected in the impactful progress they have made.

Dr. Lenardo's appointment is a significant addition to Calico's team and highlights their dedication to advancing their mission. With his expertise and experience, he is sure to make valuable contributions towards understanding aging and improving human healthspan.
Filed Under: Business

Show All News | Report Violation


Latest on Missouriar